Engineered T cells directed at tumors with defined allelic loss. (December 2020)

• Record Type: Journal Article
• Authors: Hamburger, Agnes E.; DiAndreth, Breanna; Cui, Jiajia; Daris, Mark E.; Munguia, Melanie L.; Deshmukh, Kiran; Mock, Jee-Young; Asuelime, Grace E.; Lim, Emily D.; Kreke, Michelle R.; Tokatlian, Talar; Kamb, Alexander
• Is Part Of: Molecular immunology. Volume 128(2020:Dec.)
• Page Start: 298
• Page End: 310
• Publication Date: 2020-12
• Subjects: LOH loss of heterozygosity -- LBD ligand binding domain -- ICD intracellular domain -- pMHC peptide-major-histocompatibility complex; AND NOT logic -- LOH -- CAR -- TCR -- Cell therapy -- Immuno-oncology; Immunochemistry -- Periodicals; Molecular biology -- Periodicals; Immunochemistry -- Periodicals; Allergy and Immunology -- Periodicals; Molecular Biology -- Periodicals; Immunochimie -- Périodiques; Biologie moléculaire -- Périodiques; Immunochemistry; Molecular biology; Periodicals; Electronic journals; 571.96
• DOI: 10.1016/j.molimm.2020.09.012
• Languages: English
• ISSNs: 0161-5890

Abstract

Graphical abstract: Highlights: A synthetic signal integration system taps into a large, new class of cancer targets. Takes advantage of common loss of heterozygosity at specific loci, such as HLA. Works robustly in Jurkat and primary T cells, and a mouse xenograft cancer model. The system, with minimal optimization, meets several requirements of a cell therapy. Abstract: We describe an approach to cancer therapy based on exploitation of common losses of genetic material in tumor cells (loss of heterozygosity) (Basilion et al., 1999; Beroukhim et al., 2010). This therapeutic concept addresses the fundamental problem of discrimination between tumor and normal cells and can be applied in principle to the large majority of tumors. It utilizes modular activator/blocker elements that integrate signals related to the presence and absence of ligands displayed on the cell surface (Fedorov et al., 2013). We show that the targeting system works robustly in vitro and in a mouse cancer model where absence of the HLA-A*02 allele releases a brake on engineered T cells activated by the CD19 surface antigen. This therapeutic approach potentially opens a route toward a large, new source of cancer targets.